Genvax Technologies develops next-generation mRNA and nanoparticle vaccines to prevent and treat animal diseases, leveraging advanced genetic engineering techniques. The company addresses the need for effective vaccination solutions in livestock, enhancing animal health and productivity.
Funding
$11.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current animal vaccines may not provide sufficient protection against rapidly evolving pathogens, leading to outbreaks and economic losses for livestock producers. Traditional vaccine development methods can be slow and may not be easily adaptable to new or emerging animal diseases.
Solution
Genvax Technologies is developing next-generation mRNA vaccines for animal health, utilizing advanced genetic engineering and nanoparticle delivery systems. Their approach allows for rapid development and deployment of vaccines that can be quickly adapted to address new viral strains or diseases. By leveraging mRNA technology, Genvax aims to provide more effective and adaptable vaccine solutions for livestock, improving animal health and productivity. The company focuses on creating vaccines that stimulate a strong immune response, offering enhanced protection against a range of animal diseases.
Target Audience
The primary target audience includes livestock producers, veterinarians, and animal health companies seeking advanced vaccine solutions for disease prevention in animals.
Features
- mRNA vaccine platform for rapid development and deployment
- Nanoparticle delivery system for enhanced immune response
- Adaptable vaccine design to address emerging viral strains
- Focus on livestock diseases